Derma Sciences, Inc (DSCI)

[surf1944]

7:30AM Derma Sciences on track to begin phase 3 program with DSC127 in December following meeting with FDA (DSCI) 11.50 : Co reported that based on a meeting held last week with the FDA, the Company plans to begin its Phase 3 program in December 2012 in support of a New Drug Application (NDA) for DSC127 for treatment of diabetic foot ulcers. The FDA has expressed concurrence with the Company's Chemistry, Manufacturing and Controls program.